Blocking Interleukin-6 Activity with Chimeric Anti-IL6 Monoclonal Antibodies in Multiple Myeloma: Effects on Soluble IL6 Receptor and Soluble gp130

References

• Kishimoto T., Akira S., Taga T. IL-6 and its receptor: A paradigm for cytokines. Science 1992; 258: 593–597
   PubMed Web of Science ®Google Scholar
• Yamasaki K., Taga T., Hirata Y., Yawaka H., Kawanishi Y., Seed B., Taniguchi T., Hirano T., Kishimoto T. Cloning and expression of the human IL-6 (BSF-2/IFN b2) receptor. Science 1988; 241: 825–828
   PubMed Web of Science ®Google Scholar
• Taga T., Hibi M., Hirata Y., Yamasaki K., Yasukawa K., Matsuda T., Hirano T., Kishimoto T. IL-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989; 58: 573–581
   PubMed Web of Science ®Google Scholar
• Kishimoto T., Akira S., Narazaki M., Taga T. IL-6 family of cytokines and gp130. Blood 1995; 86: 1243–1254
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.G, Lu Z.Y., Bataille R. IL-6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishi-Hara Y., Yancopoulos G., Taga T., Kishimoto T. Soluble forms of the IL-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993; 82: 1120–1126
   PubMed Web of Science ®Google Scholar
• Lust J., Donovan K., Kline M., Greipp P., Kyle R., Maihle N. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine 1992; 4: 96–100
   PubMed Web of Science ®Google Scholar
• Mullberg J., Schooltink H., Stoyan T., Gunther M., Graeve L., Buse G., Mackiewicz A., Heinrich P., Rose-John S. The soluble IL-6 receptor is generated by shedding. European Journal of Immunology 1993; 23: 473–480
   PubMed Web of Science ®Google Scholar
• Rose-John S., Heinrich P. Soluble receptors for cytokines and growth factors: generation and biological function (review). Biochemical Journal 1994; 300: 281–290
   PubMed Web of Science ®Google Scholar
• Anderson K., Jones R., Morimoto C., Leavitt P., Barut B. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73: 1915–1924
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang XG., Klein B. Serum levels of IL6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation 1989; 84: 2008–2011
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanaka H., Kuramoto A., Kishimoto T. Autocrine generation and requirement of BSF 2/IL6 for human multiple myelomas. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.G, Jourdan M., Content J., Houssiau J., Aarden L.A, Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X.G, Jourdan M., Boiron J., Portier M., Lu Z., Wijdenes J., Brochier J., Bataille R. IL6 is the central tumor growth factor in vitro and in vivo in multiple myeloma (review). European Cytokine Network 1990; 1: 193–201
   PubMedGoogle Scholar
• Nordan R., Pumphrey J., Rudikoff S. Purification and NH2-terminal sequence of a plasmacytoma growth-factor derived from the murine macrophage cell line P 388 Dl. Journal of Immunology 1987; 139: 813–817
   PubMed Web of Science ®Google Scholar
• Van Oers M.H.J., van Zaanen H.C.T., Lokhorst H.M. Interleukin-6, a new target for therapy in multiple myeloma? (review). Annals of Hematology 1993; 66: 219–223
   PubMed Web of Science ®Google Scholar
• Zhang X.G, Klein B., Bataille R. IL6 is a potent myeloma cell growth factor in patients with aggressive MM. Stood 1989; 74: 11–13
   Google Scholar
• Gaillard J.P, Bataille R., Brailly H., Zuber C., Yasukawa K., Attal M., Maruo N., Taga T., Kishimoto T., Klein B. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology 1993; 23: 820–824
   PubMed Web of Science ®Google Scholar
• Pulkki K., Pelliniemi T.T, Rajamaki A., Tienhaara A., Laakso M., Lahtinen R. Soluble IL-6 receptor as a prognostic factor in multiple myeloma. British Journal of Haematology 1996; 92: 370–374
   PubMed Web of Science ®Google Scholar
• Portier M., Lees D., Caron E., Jourdan M., Boiron J.M, Bataille R., Klein B. Up-regulation of IL-6 receptor gene expression in vitro and in vivo in IL-6 deprived myeloma cells. FEBS letters 1992; 302: 35–38
   PubMed Web of Science ®Google Scholar
• Durie B., Salmon S. Multiple myeloma, macroglobulinemia and monoclonal gammopathie. Recent advances in haematology, A.V. Hoffbrand, M.C. Brown, J. Hirsch. Churchill Livingstone, Edinburgh 1977; 243–261
   Google Scholar
• Brakenhoff J., Hart M., de Groot E., Di Padova F., Aarden L.A. Structure-function analysis of human IL6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. Journal of Immunology 1990; 145: 561–568
   PubMed Web of Science ®Google Scholar
• Ehlers M., Grotzinger J., de Hon E., Mullberg J., Brakenhoff J., Liu J., Wollmer A., Rose-John S. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. Journal of Immunology 1994; 153: 1744–1751
   PubMed Web of Science ®Google Scholar
• Van Zaanen H.C.T., Koopmans R.P, Aarden L.A, Rensink H.J, Stouthard J., Warnaar S.O, Lokhorst H.M., van Oers M.H.J. Endogenous IL6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed back loop. Journal of Clinical Investigation 1996; 98: 1441–1448
   PubMed Web of Science ®Google Scholar
• Aarden L.A, de Groot E., Schaap O., Lansdorp P. Production of hybridoma growth factor by human monocytes. European Journal of Immunology 1987; 17: 1411–1416
   PubMed Web of Science ®Google Scholar
• Aarden L. Plasmacytomas. Mechanisms of B cell neoplasm, F. Melchens, M. Potter. Editione Roche, BaselSwitzerland 1991; 429–433
   Google Scholar
• Van Zaanen H.C.T., Lokhorst H.M, Aarden L.A, Rensink H.J, Warnaar S.O., van Oers M.H.J. Phase I/II multiple-dose pilot study of chimeric anti-IL6 monoclonal antibodies in multiple myeloma (Abstr.). British Journal of Haematology 1994; 87(Suppl. I)238
   Google Scholar
• Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., Osugi Y., Tokunaga T., Kishimoto T. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. Journal of Immunology 1992; 148: 2175–2180
   PubMed Web of Science ®Google Scholar
• Yokoyama A., Kohno N., Hirasawa Y., Kondo K., Abe M., Inoue Y., Fujioka S., Fujino S., Ishida S., Hiwada K. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clinical Experimental Immunology 1995; 100: 325–329
   PubMed Web of Science ®Google Scholar
• Ohtani K., Ninomiya H., Hasegawa Y., Kobayashi T., Kojima H., Nagasawa T., Abe T. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscraias. British Journal of Haematology 1995; 91: 116–120
   PubMed Web of Science ®Google Scholar
• Kyrtsonis M., Dedoussis G., Zervas C., Perifanis V., Baxevanis C., Stamatelou M., Maniatis A. Soluble interleukin-6 receptor, a new prognostic factor in multiple myeloma. British Journal of Haematology 1996; 93: 398–400
   PubMed Web of Science ®Google Scholar
• Smith S., Morgan L. Clinical significance of elevated soluble interleukin 6 receptor levels in patients with plasma cell disorders. British Journal of Haematology 1996; 92: 766–773, letter
   Google Scholar
• Kang H., Lee B., Yang Y., Park C., Ha H., Pyun K., Choi I. Roles of protein phosphatase 1 and 2A in an IL6-mediated autocrine growth loop of human myeloma cells. Cellular Immunology 1996; 168: 174–183
   PubMed Web of Science ®Google Scholar
• Heinrich P., Castell J., Andus T. IL6 and the acute phase response (review). Biochemical Journal 1990; 265: 621–636
   PubMed Web of Science ®Google Scholar
• Coulie P.G, Stevens M., Van Snick J. High- and low-affinity receptors for murine interleukin 6. Distinct distribution on B and T cells. European Journal of Immunology 1989; 19: 2107–2114
   PubMed Web of Science ®Google Scholar
• Tura S., Cavo M. Allogeneic bone marrow transplantation in multiple myeloma. Hematology/oncology clinics of North America, B. Barlogie. W.B. Saunders Company, PhiladelphiaU.S. 1992; page 433
   Google Scholar
• Hibi M., Murakami M., Saito M., Hirano T., Taga T., Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63: 1149–1157
   PubMed Web of Science ®Google Scholar
• Lokhorst H.M, Lamme T., de Smet M., Klein S., de Weger R., van Oers M. H.J, Bloem A. Primary tumor cells of myeloma patients induce IL6 secretion in long-term bone marrow cultures. Blood 1994; 84: 2269–2277
   PubMed Web of Science ®Google Scholar
• Bellido T., Stahl N., Farruggella T., Borba V., Yancopoulos G., Manolagas C. Detection of receptors for interleukin-6, interleukin-11, LIF, Oncostatin M., and CNTF in bone marrow stromal/ osteoblastic cells. Journal of Clinical Investigation 1996; 97: 431–437
   PubMed Web of Science ®Google Scholar